LIB-01: Side Effects

Safety Overview#

LIB-01 has been evaluated in a Phase 1 first-in-human study in healthy male volunteers (single doses 10-150 mg and multiple doses over 3 days) and a Phase 2a study in 156 men with erectile dysfunction (25 mg and 50 mg). Across both studies, LIB-01 was described as safe and well tolerated at all dose levels tested.

Detailed adverse event data have been reported primarily from the Phase 1 study, with the Phase 2a safety data available only in summary form from press releases and conference presentations. No full peer-reviewed safety publications are available as of early 2026.

Gastrointestinal Adverse Events#

The most commonly reported adverse effects with LIB-01 are gastrointestinal in nature, consistent with many oral investigational compounds:

• Nausea: Reported in Phase 1 SAD and MAD cohorts
• Vomiting: Reported in Phase 1 studies
• Diarrhea: Reported in Phase 1 studies
• Frequent bowel movements: Noted as an associated GI symptom

These GI effects typically occurred within 24 hours of dosing and were described as mild. Given that LIB-01's treatment course is only 3 days, the window of potential acute GI adverse effects is limited compared to chronically dosed medications.

Melanocortin-Related Considerations#

LIB-01 modulates the melanocortin-4 receptor (MC4R) pathway. Based on the known pharmacology of MC4R and experience with other melanocortin receptor agonists, potential class-related effects to monitor include:

• Nausea: MC4R activation in the brainstem can cause nausea (well-documented with bremelanotide and setmelanotide)
• Skin flushing: Melanocortin receptor activation can cause transient facial flushing
• Blood pressure changes: MC4R plays a role in cardiovascular regulation; bremelanotide carries a blood pressure warning
• Skin hyperpigmentation: Melanocortin receptors (particularly MC1R) regulate melanogenesis, though LIB-01's reported MC4R selectivity may limit this effect

Whether these class-related effects occur with LIB-01 specifically has not been detailed in published data. The compound's mechanism of MC4R upregulation rather than direct agonism may produce a different side effect profile compared to direct melanocortin agonists.

Phase 2a Safety Summary#

Dicot Pharma reported that treatment with LIB-01 was "well tolerated at all dose levels" in the Phase 2a study. Detailed frequency data for individual adverse events, serious adverse events, and discontinuations due to adverse events have not been publicly reported from this trial.

Known Unknowns#

Given the early development stage, several important safety questions remain unanswered:

• Long-term safety: No data beyond 8 weeks of observation
• Repeated dosing safety: Effects of multiple 3-day courses over months or years are unknown
• Cardiovascular safety: No dedicated cardiovascular safety assessment has been reported
• Reproductive toxicology: Effects on fertility, pregnancy, and fetal development have not been published
• Drug-drug interactions: No formal interaction studies have been reported
• Hepatic and renal safety: Effects on liver and kidney function have not been detailed
• CNS effects: Given the central mechanism of action, potential effects on mood, sleep, or cognition require evaluation

Contraindications#

As an investigational compound, formal contraindications have not been established through regulatory review. Based on the mechanism of action and general pharmacological principles:

• LIB-01 should not be used outside of regulated clinical trials
• Women, children, and adolescents have not been studied
• Patients with known hypersensitivity to phragmalin limonoids or related compounds should exercise caution

Drug Interactions#

No formal drug-drug interaction studies have been published for LIB-01. Potential areas of concern include:

• Other melanocortin active agents: Concomitant use with bremelanotide (PT-141) or setmelanotide could theoretically produce additive melanocortin pathway activation
• PDE5 inhibitors: Combination with sildenafil, tadalafil, or similar drugs has not been studied; additive pro-erectile effects are theoretically possible through complementary peripheral and central mechanisms
• CYP metabolism: Whether LIB-01 is a substrate for or interacts with CYP enzymes has not been published

Related Reading#

• LIB-01 overview and research guide
• LIB-01 dosing protocols
• LIB-01 risks and legal status